(APLT) Applied Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03828A1016

APLT: Treatments, Medicines, Enzyme, Inhibitors, Pharmaceuticals

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York., Web URL: https://www.appliedtherapeutics.com

Additional Sources for APLT Stock

APLT Stock Overview

Market Cap in USD 75m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2019-05-14

APLT Stock Ratings

Growth 5y -78.1%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -88.8
Analysts 4/5
Fair Price Momentum 0.35 USD
Fair Price DCF -

APLT Dividends

No Dividends Paid

APLT Growth Ratios

Growth Correlation 3m -96.3%
Growth Correlation 12m -23.9%
Growth Correlation 5y -65%
CAGR 5y -57.55%
CAGR/Mean DD 5y -0.73
Sharpe Ratio 12m -0.83
Alpha -130.35
Beta 1.88
Volatility 100.64%
Current Volume 4493.7k
Average Volume 20d 3268.6k
What is the price of APLT stocks?
As of February 19, 2025, the stock is trading at USD 0.59 with a total of 4,493,658 shares traded.
Over the past week, the price has changed by +2.27%, over one month by -10.04%, over three months by -93.19% and over the past year by -88.90%.
Is Applied Therapeutics a good stock to buy?
No, based on ValueRay Analyses, Applied Therapeutics (NASDAQ:APLT) is currently (February 2025) a stock to sell. It has a ValueRay Growth Rating of -78.10 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of APLT as of February 2025 is 0.35. This means that APLT is currently overvalued and has a potential downside of -40.68%.
Is APLT a buy, sell or hold?
Applied Therapeutics has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy APLT.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for APLT stock price target?
According to ValueRays Forecast Model, APLT Applied Therapeutics will be worth about 0.4 in February 2026. The stock is currently trading at 0.59. This means that the stock has a potential downside of -28.81%.
Issuer Forecast Upside
Wallstreet Target Price 5.9 903.4%
Analysts Target Price 5.9 903.4%
ValueRay Target Price 0.4 -28.8%